CalciMedica (NASDAQ:CALC) Posts Quarterly Earnings Results, Beats Expectations By $1.03 EPS

CalciMedica (NASDAQ:CALC) posted its quarterly earnings data on Tuesday. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($1.27) by $1.03, FiscalAI reports.

CalciMedica Stock Down 3.3%

CALC stock traded down $0.05 during midday trading on Tuesday, reaching $1.47. 1,439 shares of the company were exchanged, compared to its average volume of 175,517. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. CalciMedica has a 1-year low of $1.00 and a 1-year high of $36.00. The stock’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $3.50. The company has a market cap of $10.01 million, a price-to-earnings ratio of -0.22 and a beta of 0.84.

Analyst Ratings Changes

A number of research firms have commented on CALC. Guggenheim began coverage on CalciMedica in a research note on Thursday, August 20th. They set a “buy” rating on the stock. Wall Street Zen cut CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Finally, UBS Group reissued a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, CalciMedica currently has an average rating of “Hold” and an average price target of $50.00.

About CalciMedica

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.